Esperion Therapeutics (NASDAQ: ESPR)
Esperion Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Esperion Therapeutics Company Info
Esperion Therapeutics, Inc. is a pharmaceutical company. It engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.
News & Analysis
Why Esperion Therapeutics Plummeted by 11% Today
Shareholders were displeased with the company's latest financial move.
Why Esperion Pharmaceuticals Plummeted by Nearly 22% Today
It was all about the earnings.
Why Esperion Therapeutics Stock Is Falling Today
The company gave a sneak peek into its fourth-quarter financial results.
3 New Drug Launches of 2020 -- and the Stocks That Could Win Big
Sales of these recently launched products could make a big difference for the companies behind them.
Should You Buy These 4 Biotech Stocks With Recent Drug Approvals?
These companies scored recent drug approvals. It's worth looking into their stocks to see if they're a buy now.
FDA Approves Esperion Therapeutics' New Cholesterol Drug
Millions of patients who don't respond well enough to statins now have another affordable alternative.
4 Dates Biotech Investors Should Circle in February
From a niche contraceptive to the world's top cancer treatment, the FDA has a number of interesting drugs its reviewing this month.
European Advisory Group Backs Esperion's Cholesterol Drugs
The committee vote puts bempedoic acid on the path for likely approval by the European Medicines Agency.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.